Revolution Medicines (NASDAQ:RVMD) Insider Mark Goldsmith Sells 12,871 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Mark Goldsmith sold 12,871 shares of the firm’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $1,280,407.08. Following the sale, the insider owned 276,698 shares in the company, valued at approximately $27,525,917.04. The trade was a 4.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Revolution Medicines Price Performance

Revolution Medicines stock traded up $1.18 during midday trading on Thursday, hitting $99.29. 1,485,201 shares of the company were exchanged, compared to its average volume of 2,335,170. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $124.49. The company’s fifty day moving average price is $103.58 and its 200-day moving average price is $76.24. The company has a debt-to-equity ratio of 0.16, a quick ratio of 7.14 and a current ratio of 7.14.

Revolution Medicines (NASDAQ:RVMD) last posted its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same quarter in the prior year, the firm posted ($1.12) EPS. Equities research analysts anticipate that Revolution Medicines, Inc. will post -3.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Indiana Trust & Investment Management Co bought a new position in Revolution Medicines during the 4th quarter worth $32,000. Global Retirement Partners LLC lifted its stake in Revolution Medicines by 1,002.8% in the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after buying an additional 361 shares during the last quarter. Torren Management LLC acquired a new position in shares of Revolution Medicines during the fourth quarter valued at $33,000. Arax Advisory Partners bought a new position in shares of Revolution Medicines during the fourth quarter worth about $38,000. Finally, GAMMA Investing LLC grew its position in shares of Revolution Medicines by 45.1% during the third quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock worth $39,000 after acquiring an additional 260 shares during the last quarter. Institutional investors own 94.34% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on RVMD shares. Evercore upgraded Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, February 25th. Weiss Ratings reissued a “sell (d-)” rating on shares of Revolution Medicines in a report on Thursday, January 22nd. Jefferies Financial Group started coverage on Revolution Medicines in a research note on Monday. They set a “buy” rating for the company. Wedbush reaffirmed an “outperform” rating on shares of Revolution Medicines in a research report on Friday, January 9th. Finally, UBS Group assumed coverage on Revolution Medicines in a research note on Friday, February 27th. They set a “buy” rating for the company. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $78.94.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.